Frontiers in Genetics,
Journal Year:
2023,
Volume and Issue:
14
Published: April 3, 2023
In
the
last
years,
liquid
biopsy
gained
increasing
clinical
relevance
for
detecting
and
monitoring
several
cancer
types,
being
minimally
invasive,
highly
informative
replicable
over
time.
This
revolutionary
approach
can
be
complementary
may,
in
future,
replace
tissue
biopsy,
which
is
still
considered
gold
standard
diagnosis.
"Classical"
often
cannot
provide
sufficient
bioptic
material
advanced
screening,
isolated
information
about
disease
evolution
heterogeneity.
Recent
literature
highlighted
how
of
proteomic,
genomic,
epigenetic,
metabolic
alterations.
These
biomarkers
detected
investigated
using
single-omic
and,
recently,
combination
through
multi-omic
approaches.
review
will
an
overview
most
suitable
techniques
to
thoroughly
characterize
tumor
their
potential
applications,
highlighting
importance
integrated
multi-omic,
multi-analyte
approach.
Personalized
medical
investigations
soon
allow
patients
receive
predictable
prognostic
evaluations,
early
diagnosis,
subsequent
Biomolecular Detection and Quantification,
Journal Year:
2019,
Volume and Issue:
17, P. 100087 - 100087
Published: March 1, 2019
An
increasing
number
of
studies
demonstrate
the
potential
use
cell-free
DNA
(cfDNA)
as
a
surrogate
marker
for
multiple
indications
in
cancer,
including
diagnosis,
prognosis,
and
monitoring.
However,
harnessing
full
cfDNA
requires
(i)
optimization
standardization
preanalytical
steps,
(ii)
refinement
current
analysis
strategies,
and,
perhaps
most
importantly,
(iii)
significant
improvements
our
understanding
its
origin,
physical
properties,
dynamics
circulation.
The
latter
knowledge
is
crucial
interpreting
associations
between
changes
baseline
characteristics
clinical
manifestations
cancer.
In
this
review
we
explore
recent
advancements
highlight
gaps
concerning
each
point
contact
different
stages
cancer
management.
Genome Medicine,
Journal Year:
2020,
Volume and Issue:
12(1)
Published: March 19, 2020
The
analysis
of
circulating
tumor
cells
(CTCs)
is
an
outstanding
tool
to
provide
insights
into
the
biology
metastatic
cancers,
monitor
disease
progression
and
with
potential
for
use
in
liquid
biopsy-based
personalized
cancer
treatment.
These
goals
are
ambitious,
yet
recent
studies
already
allowing
a
sharper
understanding
strengths,
challenges,
opportunities
provided
by
biopsy
approaches.
For
instance,
through
single-cell-resolution
genomics
transcriptomics,
it
becoming
increasingly
clear
that
CTCs
heterogeneous
at
multiple
levels
only
fraction
them
capable
initiating
metastasis.
It
also
appears
adopt
ways
enhance
their
potential,
including
homotypic
clustering
heterotypic
interactions
immune
stromal
cells.
On
clinical
side,
both
CTC
enumeration
molecular
may
new
means
take
individualized
treatment
decisions,
but
early
detection
be
challenging
compared
other
derivatives
such
as
DNA.
In
this
review,
we
summarize
current
data
on
CTC-based
applications
likely
impact
our
process
influence
management
patients
cancer,
prospects
favor
implementation
precision
medicine.
Hepatology,
Journal Year:
2020,
Volume and Issue:
73(1), P. 422 - 436
Published: Feb. 4, 2020
Hepatocellular
carcinoma
(HCC)
is
among
the
leading
causes
of
worldwide
cancer-related
morbidity
and
mortality.
Poor
prognosis
HCC
attributed
primarily
to
tumor
presentation
at
an
advanced
stage
when
there
no
effective
treatment
achieve
long
term
survival
patients.
Currently
available
tests
such
as
alpha-fetoprotein
have
limited
accuracy
a
diagnostic
or
prognostic
biomarker
for
HCC.
Liver
biopsy
provides
tissue
that
can
reveal
biology
but
it
not
used
routinely
due
its
invasiveness
risk
seeding,
especially
in
early-stage
also
revealing
comprehensive
intratumoral
heterogeneity.
There
clear
need
new
biomarkers
improve
detection,
prognostication,
prediction
response,
disease
monitoring
with
treatment.
Liquid
could
be
method
early
detection
management
Circulating
cells
(CTCs)
are
cancer
circulation
derived
from
original
metastatic
foci,
their
measurement
by
liquid
represents
great
potential
facilitating
implementation
precision
medicine
patients
CTCs
detected
simple
peripheral
blood
draw
potentially
show
global
features
characteristics.
Various
CTC
platforms
using
immunoaffinity
biophysical
properties
been
developed
identify
capture
high
efficiency.
Quantitative
abundance
CTCs,
well
biological
characteristics
genomic
heterogeneity
predict
response
therapy
This
review
article
will
discuss
currently
technologies
isolation,
utility
clinical
patients,
limitations,
future
directions
research.
Cancer Letters,
Journal Year:
2019,
Volume and Issue:
468, P. 59 - 71
Published: Oct. 12, 2019
Liquid
biopsies
hold
the
potential
to
inform
cancer
patient
prognosis
and
guide
treatment
decisions
at
time
when
direct
tumor
biopsy
may
be
impractical
due
its
invasive
nature,
inaccessibility
associated
complications.
Specifically,
circulating
DNA
(ctDNA)
cells
(CTCs)
have
shown
promising
results
as
companion
diagnostic
biomarkers
for
screening,
prognostication
and/or
surveillance
in
many
types.
In
ovarian
(OC),
CTC
ctDNA
analysis
allow
comprehensive
molecular
profiling
of
primary,
metastatic
recurrent
tumors.
These
also
correlate
with
overall
burden
thus,
they
provide
minimally-invasive
means
monitoring
during
clinical
course
ascertain
therapy
response
timely
modification
context
disease
relapse.
Here,
we
review
recent
reports
value
OC,
expatiating
on
their
use
diagnosis
prognosis.
We
critically
appraise
current
evidence,
discuss
issues
that
still
need
addressed
before
liquid
can
implemented
routine
practice
OC
management.
The Innovation,
Journal Year:
2022,
Volume and Issue:
3(4), P. 100259 - 100259
Published: May 6, 2022
Effective
screening
modalities
are
currently
available
for
only
a
small
subset
of
cancers,
and
they
generally
have
suboptimal
performance
with
complicated
procedures.
Therefore,
there
is
an
urgent
need
to
develop
simple,
accurate,
non-invasive
methods
early
detection
cancers.
Genetic
epigenetic
alterations
in
plasma
circulating
cell-free
DNA
(cfDNA)
shown
the
potential
revolutionize
cancers
facilitate
subsequent
diagnosis
improve
survival
patients.
The
medical
interest
cfDNA
assays
has
been
inspired
by
emerging
single-
multi-early
studies.
This
review
summarizes
current
technological
clinical
advances,
hopes
providing
insights
into
development
applications
various
scenarios.
key
phases
biomarkers
highlighted,
future
developments
cfDNA-based
liquid
biopsies
outlined.
It
hoped
that
this
study
can
boost
integration
workflow.
Medicina,
Journal Year:
2021,
Volume and Issue:
57(1), P. 62 - 62
Published: Jan. 12, 2021
Triple-negative
breast
cancer
(TNBC)
is
an
aggressive
type
of
with
no
expression
estrogen
receptor
(ER),
progesterone
(PR),
and
human
epidermal
growth
factor
receptor-2
(HER2).
It
a
highly
metastasized,
heterogeneous
disease
that
accounts
for
10–15%
total
cases
poor
prognosis
high
relapse
rate
within
five
years
after
treatment
compared
to
non-TNBC
cases.
The
diagnostic
subtyping
TNBC
tumors
are
essential
determine
the
alternatives
establish
personalized,
targeted
medications
every
individual.
Currently,
diagnosed
via
two-step
procedure
imaging
immunohistochemistry
(IHC),
which
operator-dependent
potentially
time-consuming.
Therefore,
there
crucial
need
development
rapid
advanced
technologies
enhance
efficiency
TNBC.
This
review
discusses
overview
emphasis
on
subtypes
current
approaches
along
its
challenges.
Most
importantly,
we
have
presented
several
promising
strategies
can
be
utilized
as
future
modalities
simultaneously
efficacy
diagnostic.
Cell Genomics,
Journal Year:
2023,
Volume and Issue:
3(1), P. 100242 - 100242
Published: Jan. 1, 2023
The
high
fragmentation
of
nuclear
circulating
DNA
(cirDNA)
relies
on
chromatin
organization
and
protection
or
packaging
within
mononucleosomes,
the
smallest
most
stabilized
structure
in
bloodstream.
detection
differing
size
patterns,
termed
fragmentomics,
exploits
information
about
nucleosomal
packing
DNA.
Fragmentomics
not
only
implies
pattern
characterization
but
also
considers
positioning
occupancy
nucleosomes,
which
result
cirDNA
fragments
being
protected
persisting
circulation.
can
determine
tissue
origin
distinguish
cancer-derived
cirDNA.
screening
power
fragmentomics
has
been
considerably
strengthened
omics
era,
as
shown
ongoing
development
sophisticated
technologies
assisted
by
machine
learning.
thus
be
regarded
a
strategy
for
characterizing
cancer
individuals
offers
an
alternative
synergistic
supplement
to
mutation
searches,
methylation,
nucleosome
positioning.
As
such,
it
potential
improving
diagnostics
screening.
